 |
|
A new pharmaceutical drug that halts progress of metastatic kidney cancer
March 02, 2007Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer. The work was published recently in the prestigious international medical journal, The New England Journal of Medicine and involved medical co-researchers from the Oncology Department of the University Hospital of Navarra, in collaboration with the Clinical Trials Area of the same Department.
To date the usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. In phase III of the research sunitinib was compared with interferon (a type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that sunitinib is more efficient in halting the progress of the disease. 101 medical centres from all over the world took part in the research.
Given the short period of follow-up in the research, the effect of the treatment on survival rates could not be corroborated. Although, in general, the treatment is well tolerated, certain side effects can occur and have to be taken into consideration-hypothyroidism, high blood pressure and fatigue.
Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer. The mechanism of functioning of sunitinib is in blocking the generation of new blood vessels. Tumours, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is to be approved shortly for the treatment of kidney cancer with metastasis although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.
Elhuyar Fundazioa
Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer. The mechanism of functioning of sunitinib is in blocking the generation of new blood vessels. Tumours, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is to be approved shortly for the treatment of kidney cancer with metastasis although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.
Elhuyar Fundazioa
Kidney Cancer Current Events and Kidney Cancer News RSSNew data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas
Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.
Stem cell protein offers a new cancer target
A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.
2-drug combination appears safe and active in metastatic kidney cancer
Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial.
Finding Will Improve Accuracy of Cancer Diagnosis
Van Andel Research Institute (VARI) investigators working in collaboration with Cleveland Clinic researchers have determined that two types of kidney tumors previously thought to be different diseases are actually variations of the same disease.
Does a person's insurance coverage affect their access to quality cancer care?
Does a person's insurance coverage affect their access to quality cancer care? According to researchers at Fox Chase Cancer Center, insurance coverage may not only affect a patient's access to health care, but also the quality of care they receive.
Robotic assisted kidney cancer surgery proves to be beneficial to patients
Fox Chase Cancer Center researchers find that outcomes of robotic assisted kidney cancer surgery, when performed by experienced surgeons at high volume centers, prove more beneficial to patients when compared to open surgery.
Getting down to cancer basics
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes. The new example - a gene on the X chromosome called UTX - is found in 10% of cases of multiple myeloma and 8% of esophageal cancers.
Castrate resistant prostate cancer: New therapeutic approaches
Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.
Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
Freezing kidney tumors-using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery-should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller. And, this treatment-interventional cryoablation-is a viable option for people with larger tumors, according to two studies presented at the Society of Interventional Radiology's 34th Annual Scientific Meeting.
Roadkill study could speed detection of kidney cancer
Large-scale data mining of gene networks in fruit flies has led researchers to a sensitive and specific diagnostic biomarker for human renal cell carcinoma, the most common type of kidney cancer.
More Kidney Cancer Current Events and Kidney Cancer News Articles
 |
100 Questions & Answers About Kidney Cancer (100 Questions & Answers about) by Steven C. Campbell (Author) There are 37,000 cases of kidney (renal cell) cancer in the US and 13,000 related deaths annually. 100 Questions and Answers About Kidney Cancer explains all aspects of the disease resulting in full awareness of what to expect when battling kidney cancer. |
 |
Johns Hopkins Patients' Guide to Kidney Cancer by Michael A. Carducci (Author) Johns Hopkins Patients' Guide to Kidney Cancer is a concise how to guide that puts you on a path to wellness by explaining kidney cancer treatment. It guides you through the maze of treatment decisions, simplifies the schedule, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your treatment. |
 |
Nothing to Fear by Larry Burkett (Author) In Nothing to Fear, Larry Burkett tells his personal journey of a seven-year battle with cancer. Filled with intimate stories and wisdom from the Word, this book will be a great help to the thousands of people who fight this disease, or to friends and loved ones of those in the midst of the struggle. Larry's 2003 passing was the result of heart failure rather than cancer. His legacy continues today and his words still bring hope to those in need of encouragement. 'Even if you can avoid dying from cancer, you'll certainly face something else that will eventually kill you, because all of us are going to die. As god as modern medicine is, it is not the ultimate answer. It will let you down. Trusting God is the answer. He will never let you down.' -Excerpt from Nothing to Fear |
 |
Kidney Cancer: A New Approach Most people have two functional kidneys which help regulate electrolytes such as sodium, potassium, calcium, and magnesium. Kidney tumors may change these important functions and can lead to a diagnosis of kidney cancer. On this program we spend time with courageous patients who are coping with their kidney cancer by seeking a new approach. Kidney Cancer is part of the award winning public television series Healthy Body, Healthy Mind. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Carcinoma of the Kidney (Contemporary Issues in Cancer Imaging) by Uday Patel (Editor) The last two decades have seen ground-shifting changes in the epidemiology, genetics, diagnosis and management of renal cancer. Advances in diagnosis have led to many tumours being identified at an asymptomatic stage. There have also been parallel advances in treatment, such as nephron sparing procedures and radiologically guided ablative procedures. However, these changes have brought with them dilemmas such as our ability to evaluate the nature and aggressiveness of early stage tumours and how best to identify those patients who will benefit most from early treatment. This practical, clinically-oriented volume focuses on these current diagnostic and clinical challenges, making it relevant to all members of the multidisciplinary cancer care team. |
 |
Kidney Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Kidney Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Kidney Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Kidney Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Anatomical Human Diseased Kidney Cancer Model by GPI This oversized 2-sided kidney model has a nomal anatomy cutaway on one side and a diseased anatomy cutaway on the other side depicting: infection, scarring, atrophy, urinary (kidney) stones, tumor, polycystic disease, hypertension effects. Size: 3 3/4" x 2 1/2" x 6 1/2" Includes stand and detailed instructional card. Ideal for clinical display and consumer education. |
 |
Kidney Cancer: The Silent Destroyer Directed By: (c) Information Television Network |
 |
Beating Kidney Cancer Together Sweatshirt XXX-Large White by Shop Zeus |
 |
Dx/ Rx: Genitourinary Oncology: Cancer of the Kidney, Bladder, and Testis (Dx/Rx Oncology) by Matthew Galsky (Author) Designed for both oncologists and urologists, Dx/Rx: Genitourinary Oncology is a current, concise, quick reference guide to the diagnosis and therapy of cancers of the bladder/urothelial tract, kidneys, and testis. Tightly organized into a super-condensed outline-bulleted format, this handy, pocket-sized manual details precise, up-to-date information on the epidemiology, classification, diagnosis, treatment, and risk factors of genitourinary disorders. Throughout the book, tables and figures summarize important clinical data and current professional society recommendations, while salient references direct readers to additional information. |
| © 2009 BrightSurf.com |